TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05056298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Custom made insole
Description: Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises of extrinsic foot muscles
Description: Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises of extrinsic foot muscles
Description: Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening exercises of intrinsic foot muscles
Description: The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises of intrinsic foot muscles
Description: The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insole
Description: Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
Study: NCT06348498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jia Shen Tablet
Description: Jia Shen Tablets contain 4 tablets (0.47 g per tablet), take orally, 2 times a day for 12 weeks
Study: NCT05662293

Intervention type: OTHER
Intervention: Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)
Description: Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part). The assessment will be done via mail, letter or phone

Intervention type: OTHER
Intervention: Data collection: Quality of Life (QoL) Questionnaire (prospective part)
Description: Data collection: Quality of Life (QoL) Questionnaire (prospective part). The questionnaire EQ-5D-5L questionnaire will be used to assess quality of life.

Intervention type: OTHER
Intervention: Data collection (retrospective study)
Description: Anonymized search and review of patients electronic health records of the University Hospital of Basel for patients with a reduced LVEF and a concomitant (±1year or after any observation of a reduced LVEF in imaging) diagnosis of arrhythmia known to be causing AiCM.

Intervention type: OTHER
Intervention: Data collection (prospective study database)
Description: Data collection on alcohol consumption, family history, rhythm disorder, hospitalizations, cardiac assessments, adverse events at baseline, 6 months, 1 year, 2 years and 5 years.
Study: NCT05265091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL590586 Capsule
Description: Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule
Study: NCT01228110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortison

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Study: NCT04875988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Butterfly iQ+ Ultrasound
Description: ultrasound will be used in the intervention group for IV access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: ultrasound will not be used in the traditional IV placement group
Study: NCT05615870

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Winix 5500-2 HEPA filtration units
Description: To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Winix 5500-2 HEPA filtration units
Description: To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.
Study: NCT05704335

Intervention type: OTHER
Intervention: Questionnaire administration
Description: A trained physician will administer a structured questionnaire
Study: NCT04850859

Intervention type: OTHER
Intervention: measure various dimensions of the glenoid
Description: measurement of Superior-Inferior glenoid diameter ,Anterior-Posterior glenoid diameter and study shape of the glenoid cavity .

Intervention type: OTHER
Intervention: measure various dimensions of the acetabulum
Description: measurement of transverse diameter of the acetabulum ,vertical diameter of the acetabulum, depth of the acetabulum ,Width of acetabular notch and study shape of anterior acetabular ridge and ends of lunate surface .
Study: NCT04700397

Intervention type: DIAGNOSTIC_TEST
Intervention: Nitroglycerine
Description: We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
Study: NCT06525636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK8123
Description: Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK8123
Description: Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK8123
Description: Subcutaneous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK8123
Description: Subcutaneous administration
Study: NCT05751538

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06525636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK8123
Description: Subcutaneous administration
Study: NCT05751538

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03817034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia
Description: Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
Study: NCT06028581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breastfeeding support system
Description: Using the breastfeeding support system
Study: NCT06183203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomy
Description: Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Endoflas)
Study: NCT04974814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 40mg
Description: patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: patients in active arms will be preloaded with a single 80 mg atorvastatin in ER before PCI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control Test
Description: patients in control arm will not preloaded with statin in ER before PCI
Study: NCT00899587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril
Description: enalapril 5 mg every night

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen
Description: oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05903690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAG-17
Description: RAG-17 60mg is used
Study: NCT05253690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balloon catheter insertion approach for labor induction
Description: Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
Study: NCT05766618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fibrin (i-PRF): in acceleration of orthodontic tooth movement
Description: Preparatory phase~* Space closure will be done on a 17x25 stainless steel wire~* Both molars will be indirectly anchored to the miniscrew~* Extend closing coil spring of suitable length from the canine hock to the first molar hock for retraction.~* Apply a force of 150gm for each side. The force is measured by a force gauge and activated each visit to keep it constant all over the retraction phase. PRF Injection protocol~* The First injection will be 3 weeks before extraction~* By the end of the fourth week the patients will be referred for pre-intervention records. Upper arch CBCT will be obtained to take preintervention measurements of the alveolar bone.~* At the time of canine retraction patient will receive another injection immediately and an alginate impression will be taken~* follow up every month and injection will be repeated month after month with an observational period of 5 months.
Study: NCT04908904

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cafestol
Description: Capsule with 12 mg cafestol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule without cafestol
Study: NCT04791540

Intervention type: DIAGNOSTIC_TEST
Intervention: handgrip strenght
Description: Muscle strenght measured with a handheld dynamometer, at admission (T0) and at decannulation time (T1)

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: Muscle mass evaluated by Bioelectrical Impedance Analysis (BIA), at admission (T0) and at decannulation time (T1)

Intervention type: DIAGNOSTIC_TEST
Intervention: MUST
Description: Malnutrition risk assessed by Malnutrition Universal Screening Tool (MUST), at admission (T0) and at decannulation time (T1)

Intervention type: DIAGNOSTIC_TEST
Intervention: GLIM
Description: Malnutrition diagnosis performed by Global Leadership Initiative on Malnutrition (GLIM) criteria, at admission (T0) and at decannulation time (T1)

Intervention type: BIOLOGICAL
Intervention: Gut microbiota
Description: A fecal sample obtained at admission (T0) and at decannulation time (T1)

Intervention type: BIOLOGICAL
Intervention: Blood Sample
Description: A Blood sample obtained at admission (T0) and at decannulation time (T1)

Intervention type: OTHER
Intervention: Anthropometric measures
Description: Measurement of weight and height (assessed only at admission) to calculate the Body Mass Index (BMI), at admission (T0) and at decannulation time (T1)
Study: NCT05253690

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: balloon catheter insertion approach for labor induction
Description: Parous women will be randomized to labor induction by view-guided approach using a speculum for catheter insersion versus manual guided catheter balloon insersion at cervical examination
Study: NCT06364592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and SDZ-V electroacupuncture apparatus will be used. Acupoints of Ciliao (BL32), Shiqizhui (EX-B8), and Sanyinjiao (SP6) will be used for participants.~The needles will be inserted to 60-70mm in BL32 and 25-30mm in EX-B8 and SP6. Needle manipulation will be conducted (except for BL32) to achieve deqi sensation. Then paired electrodes from the electroacupuncture apparatus will be attached transversely to the needle handles at bilateral BL32 and SP6. The electroacupuncture stimulation will last for 30 minutes with a continuous wave of 5Hz and a current intensity of 1 to 5mA. Current intensity was adjusted according to the patients' individual tolerance.Treatment will start within one week before the onset of menstruation and stop before the end of menstruation, three sessions per menstrual cycle in total (ideally every two to three days and at least one session during menstruation period).
Study: NCT04944810

Intervention type: PROCEDURE
Intervention: Magnetic Gastric Bypass
Description: Perform a gastric bypass with the magnetic grasper to do the liver retraction, upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb and perform the section of the limb and finish the gastric bypass

Intervention type: PROCEDURE
Intervention: Magnetic Sleeve Gastrectomy
Description: Perform a sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach

Intervention type: PROCEDURE
Intervention: Revisional Bariatric Surgery
Description: Perform liver retraction and also steps of the surgery like upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb, upper retraction of the stomach

Intervention type: PROCEDURE
Intervention: Nissen/Sleeve Gastrectomy with Magnetic Assistance
Description: Perform a nissen-sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach, retraction of the stomach to close the hiatal defect and perform a nissen funduplication before do the sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: Mangetic General Surgery
Description: Use the magnetic grasper to do the gallbladder retraction in cholecystectomies and upper retraction of the stomach to close the defect on hiatal hernia cases.
Study: NCT05489991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TmPSMA-02
Description: Intravenous administration of genetically modified autologous T-cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) with a lentiviral vector to express anti-PSMA scFv, CD2 co-stimulatory domain and dually armored with a dominant negative TGFβ receptor and PD1.CD28 switch, will be infused intravenously on Day 0 as a single flat dose following standard lymphodepleting (LD) regimen.
Study: NCT04250233

Intervention type: DEVICE
Intervention: Respiratory Monitor
Description: All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.

Intervention type: DEVICE
Intervention: Respiratory Monitor
Description: All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.
Study: NCT04824391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERUCOV-VAC 3 µg/0.5 ml Vaccine
Description: Two IM applications on Days 1 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERUCOV-VAC 6 µg/0.5 ml Vaccine
Description: Two IM applications on Days 1 and 28

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two IM applications on Days 1 and 28
Study: NCT06166537

Intervention type: OTHER
Group type: OTHER
Intervention: Graduated compression stockings
Description: Graduated compression stockings are standard care (control)

Intervention type: OTHER
Group type: OTHER
Intervention: No Graduated compression stockings
Description: No Graduated compression stockings is the intervention
Study: NCT06424600

Intervention type: OTHER
Intervention: Gingival Index
Description: The G-I index ranging between 0.5-2 was used to calculate the occurrence of severe gingival issues in participants with smoking habits. The G-I index between 0.50-1.00 displayed light gingival inflammation, G-I between 1.10-2.00 revealed moderate gingival inflammation and G-I \> 2.00 confirmed severe gingival inflammation.

Intervention type: OTHER
Intervention: Gingival Index
Description: The G-I index ranging between 0.5-2 was used to calculate the occurrence of severe gingival issues in participants with smoking habits. The G-I index between 0.50-1.00 displayed light gingival inflammation, G-I between 1.10-2.00 revealed moderate gingival inflammation and G-I \> 2.00 confirmed severe gingival inflammation.

Intervention type: OTHER
Intervention: Gingival Index
Description: The G-I index ranging between 0.5-2 was used to calculate the occurrence of severe gingival issues in participants with smoking habits. The G-I index between 0.50-1.00 displayed light gingival inflammation, G-I between 1.10-2.00 revealed moderate gingival inflammation and G-I \> 2.00 confirmed severe gingival inflammation.
Study: NCT06344533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003142 Injection
Description: JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
Study: NCT05098067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin Topical Cream
Description: 5g 0.075% applied once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 10mg IV once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: 10mg IV once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 8mg IV once if needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 8mg IV once if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringers, Intravenous
Description: 1000cc once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringers, Intravenous
Description: 1000cc once
Study: NCT06511323

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases
Description: at baseline prior to stereotactic radiation, at 10 weeks after treatment, and at first concern for progression at treated lesion or 12 months post-treatment, whichever comes earlier.
Study: NCT05007041

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLUAD® Quadrivalent
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® High-Dose Quadrivalent
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINGRIX®
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINGRIX®
Description: Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Study: NCT05755386

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iptacopan
Description: iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Study: NCT05072964

Intervention type: DEVICE
Group type: OTHER
Intervention: FARAPULSE Pulsed Field Ablation System
Description: A pulmonary vein isolation will be performed using catheter ablation
Study: NCT06349512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46 PET/CT imaging
Description: The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.
Study: NCT05593536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education
Description: Biological feeding and classical breastfeeding trainings will be given to pregnant women by a trained nurse.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education
Description: Biological feeding and classical breastfeeding trainings will be given to pregnant women by a trained nurse.
Study: NCT04432090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Medication (MBX-2982)
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Medication (MBX-2982)
Description: Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No medication for this group
Description: This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.